Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's

PHASE3TerminatedINTERVENTIONAL
Enrollment

800

Participants

Timeline

Start Date

May 31, 2006

Study Completion Date

December 31, 2008

Conditions
Alzheimer DiseaseDementia
Interventions
DRUG

MPC-7869

Oral 800 mg BID

DRUG

MPC-7869

Oral BID dosing

Trial Locations (92)

Unknown

Phoenix

Tucson

Costa Mesa

San Diego

New Haven

Deerfield Beach

Delray Beach

Gainsville

Hollywood

Miami

Tampa

West Palm Beach

Chicago

Indianapolis

Lexington

Boston

Farmington Hills

St Louis

Rochester

Providence

Charleston

Dallas

Salt Lake City

Aalst

Antwerp

Edegem

Hasselt

Leuven

Sint-Truiden

Calgary

Medicine Hat

Vancouver

Winnipeg

Moncton

Saint John

Halifax

Kingston

London

Ottawa

Peterborough

Toronto

Greenfield Park

Montreal

Verdun

Regina

Odense

Odense C

Bordeaux

Dijon

Marseille

Montpellier

Nice

Reims

Rennes

Saint-Herblain

Toulouse

Tours

Berlin

Bochum

Bonn

Darmstadt

Düsseldorf

Freiburg im Breisgau

Hamburg

Heidelberg

Leipzig

Mannheim

München

Schwerin

Brescia

Milan

Perugia

Pisa

Roma

's-Hertogenbosch

Amsterdam

Blaricum

Barcelona

Bilbao

Getafe. Madrid

Madrid

Lund

Basel

Bath

London

Oxford

Sheffield

Swindon

Belfast

Glasgow

Penarth

Southhampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Myrexis Inc.

INDUSTRY

NCT00322036 - Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's | Biotech Hunter | Biotech Hunter